Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cystic fibrosis drug help brain bleed survivors walk again?

NCT ID NCT06723717

Disease control Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving dornase alfa (a drug already used for cystic fibrosis) daily for up to 14 days after a brain bleed from a ruptured aneurysm can help people recover better. The goal is to see if more patients can live independently at 6 months. The trial will enroll 304 adults and compares the drug to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dornase alfa (Pulmozyme®)
What this could lead to
If it works, this could offer a new treatment to prevent delayed brain damage after a ruptured aneurysm, helping more survivors regain independence.
What could go wrong
This is a Phase 2 trial with 304 participants, so results are still early. The drug has not been proven for this condition, and there is no guarantee it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 304 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hospitalization for subarachnoid hemorrhage (SAH) due to aneurysm rupture * Onset of SAH symptoms less than 48 hours old * Aneurysm exclusion performed within the last 24 hours * No complications during exclusion procedure, confirmed on post-procedure CT scan * Fisher score \> 1 on initial brain CT scan prior to exclusion (first scan performed during emergency management) Exclusion Criteria: * Unidentified date of aneurysm rupture / rebleeding * Severe infections * Patient with impaired renal function (GFR \< 60ml/min/1.73m2 or serum creatinine \>1.5 mg/dL) * Immediate complications of neurosurgical intervention or embolization * Known hypersensitivity to dornase alfa, Chinese hamster ovary cell products or product excipients. * Previous disability (mRS\>1 prior to SAH) * Pregnant or breast-feeding women (negative urine pregnancy test for women aged 49 or under) * Participation in another interventional drug or medical device clinical trial within the 30 days prior to inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delayed cerebral ischemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage brain ischemia subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Delayed cerebral ischemia Ruptured aneurysm of intracranial artery Sah (subarachnoid hemorrhage)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Poitiers

    RECRUITING

    Poitiers, Poitiers, 86000, France

  • CHU Strasbourg

    RECRUITING

    Strasbourg, Strasbourg, France

  • CHU de Grenoble

    RECRUITING

    Grenoble, Grenoble, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, Montpellier, France

  • HCL de Lyon

    RECRUITING

    Lyon, Lyon, 69002, France

  • Hôpital FOCH

    RECRUITING

    Suresnes, Île-de-France Region, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.